| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases.
|
2006
|
1.35
|
|
2
|
Resveratrol: a therapeutic promise for cardiovascular diseases.
|
2007
|
1.24
|
|
3
|
MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets.
|
2009
|
1.17
|
|
4
|
The vascular endothelin system in hypertension--recent patents and discoveries.
|
2006
|
1.16
|
|
5
|
Oxidative stress and endothelial function: therapeutic interventions.
|
2011
|
1.05
|
|
6
|
Methylglyoxal and advanced glycation endproducts: new therapeutic horizons?
|
2007
|
0.98
|
|
7
|
A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases.
|
2008
|
0.98
|
|
8
|
Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
|
2012
|
0.98
|
|
9
|
Specific antidotes in development for reversal of novel anticoagulants: a review.
|
2014
|
0.97
|
|
10
|
Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs.
|
2006
|
0.97
|
|
11
|
Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases.
|
2011
|
0.96
|
|
12
|
New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease.
|
2008
|
0.92
|
|
13
|
MicroRNA-21 as therapeutic target in cancer and cardiovascular disease.
|
2010
|
0.92
|
|
14
|
Gender differences in ischemic heart disease.
|
2009
|
0.91
|
|
15
|
Omega-3 fatty acids: from biochemistry to their clinical use in the prevention of cardiovascular disease.
|
2007
|
0.91
|
|
16
|
Rimonabant for the treatment of obesity.
|
2008
|
0.91
|
|
17
|
Ultrasound microbubble contrast and current clinical applications.
|
2011
|
0.90
|
|
18
|
Mitochondrially targeted antioxidants for the treatment of cardiovascular diseases.
|
2010
|
0.90
|
|
19
|
Oxidative stress in cardiovascular disease: a new avenue toward future therapeutic approaches.
|
2006
|
0.89
|
|
20
|
The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction.
|
2007
|
0.89
|
|
21
|
Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase.
|
2006
|
0.88
|
|
22
|
Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis.
|
2006
|
0.88
|
|
23
|
Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
|
2006
|
0.88
|
|
24
|
Bivalirudin: alternative anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
|
2010
|
0.88
|
|
25
|
Methods for identifying cardiovascular agents: a review.
|
2006
|
0.88
|
|
26
|
Actual knowledge of systemic inflammation reaction during cardiopulmonary bypass.
|
2012
|
0.88
|
|
27
|
Levosimendan for heart-operated patients: what is the state of the art?
|
2009
|
0.88
|
|
28
|
Targets for the treatment of erectile dysfunction: is NO/cGMP still the answer?
|
2007
|
0.88
|
|
29
|
Novel molecular targets in the treatment of cardiac hypertrophy.
|
2006
|
0.88
|
|
30
|
Homocysteine and heart failure: an overview.
|
2009
|
0.88
|
|
31
|
Role of PPAR in cardiovascular diseases.
|
2006
|
0.88
|
|
32
|
Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double -Edged Sword!
|
2015
|
0.87
|
|
33
|
The zebrafish as a novel tool for cardiovascular drug discovery.
|
2009
|
0.87
|
|
34
|
Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches.
|
2012
|
0.87
|
|
35
|
Anti-atherosclerotic therapy based on botanicals.
|
2013
|
0.87
|
|
36
|
MMP inhibitors in cardiac diseases: an update.
|
2007
|
0.87
|
|
37
|
Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease.
|
2008
|
0.86
|
|
38
|
Novel pharmacologic strategies to protect the liver from ischemia-reperfusion injury.
|
2008
|
0.86
|
|
39
|
Cardiovascular effects of green tea catechins: progress and promise.
|
2012
|
0.86
|
|
40
|
Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause.
|
2008
|
0.85
|
|
41
|
Circulating microparticles as therapeutic targets in cardiovascular diseases.
|
2007
|
0.85
|
|
42
|
Pharmacologic treatment for prehypertension: to treat or not to treat?
|
2009
|
0.85
|
|
43
|
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
|
2009
|
0.85
|
|
44
|
Ryanodine receptor: a novel therapeutic target in heart disease.
|
2007
|
0.85
|
|
45
|
TNNI3K could be a novel molecular target for the treatment of cardiac diseases.
|
2009
|
0.83
|
|
46
|
Statins as antihypertensives.
|
2008
|
0.83
|
|
47
|
The role of omega-3 polyunsaturated fatty acids supplementation in childhood: a review.
|
2013
|
0.82
|
|
48
|
Aldose reductase inhibition: emerging drug target for the treatment of cardiovascular complications.
|
2010
|
0.82
|
|
49
|
Interactive effect of combined exposure to active and passive smoking on cardiovascular system.
|
2011
|
0.82
|
|
50
|
Targeting MCP-1 to reduce vascular complications of obesity.
|
2009
|
0.82
|